Navigation Links
Research: Fructose not responsible for increase in non-alcoholic fatty liver disease

TORONTO, Feb. 26, 2014Non-alcoholic fatty liver disease is the most common chronic liver disease in developed countries, affecting up to 30 per cent of their populations.

Since the disease is closely linked to obesity and Type 2 diabetes, there's a growing debate in the medical community about whether diet plays a role in its development, specifically the consumption of fructose.

The possible link to non-alcoholic fatty liver disease has become the main criticism against fructose among those who believe there is something unique about the fructose molecule or the way it is metabolized and blame it for the obesity epidemic.

A meta-analysis of all available human trials published today in the European Journal of Clinical Nutrition says fructose in and of itself is not to blame for the increase in non-alcoholic fatty liver disease.

But excess consumption of calories can contribute to the disease, regardless of whether those calories came from fructose or other carbohydrates, said the lead author, Dr. John Sievenpiper, a researcher in the Clinical Nutrition and Risk Factor Modification Centre of St. Michael's Hospital.

"The one thing fructose is supposed to do above all else is give you fatty liver disease, which some say is a starting point for metabolic syndrome--a term used to describe a group of conditions that puts people at higher risk of developing Type 2 diabetes, heart disease and other heart-related problems--and Type 2 diabetes itself," Dr. Sievenpiper said.

"But we found it behaves no differently than glucose or refined starches. It is only when you consume excess calories in the form of fructose that you see a signal for harm but no more harm than if you consume excess calories as glucose."

Fructose, which is naturally found in fruit, vegetables and honey, is a simple sugar that together with glucose forms sucrose, the basis of table sugar. It is also found in sucrose and high-fructose corn syrup, the two most common sweeteners in commercially prepared foods.

Non-alcoholic fatty liver disease is one cause of a fatty liver, occurring when fat is deposited in the liver. Unlike alcoholic liver disease, it is not due to excessive alcohol use.

Previous research by Dr. Sievenpiper has found that fructose by itself does not cause weight gain and does not itself have any impact on an emerging marker for the risk of cardiovascular disease known as postprandial triglycerides when it is substituted for other carbohydrates. It is when fructose is overconsumed providing excess calories that you see the adverse effects on health, but no more than when other carbohydrates are overconsumed.

A study he published in the February issue of Current Opinion in Lipidology also found no benefit in replacing fructose with glucose in commercially prepared foods. That research again showed that that when portion sizes and calories are the same, fructose does not cause any more harm than glucose.

"The debate over the role of fructose in obesity, fatty liver and other metabolic diseases has distracted us from the issue of overconsumption," Dr. Sievenpiper said. "Our data should serve to remind people that the excess calories, whether they are from fructose or other sources, are the issue."


Contact: Leslie Shepherd
St. Michael's Hospital

Related biology news :

1. New research: Effects of eating half an avocado with lunch on satiety & desire to eat between meals
2. Pioneers in Alzheimers research: Research couple honored for its lifetime achievement
3. New research: Wolf Lake ancient forest is endangered ecosystem
4. DoD-funded research: Can climate change heat up conflict?
5. New Research: Modified Citrus Pectin - A Potent Anti-Cancer Therapy
6. PTSD research: Distinct gene activity patterns from childhood abuse
7. Dartmouth research: The clocks are ticking and the climate is changing
8. Influenza research: Can dynamic mapping reveal clues about seasonality?
9. New research: Soluble corn fiber plays important role in gut health and calcium absorption
10. Research: Many programs to help diabetics manage their health do work
11. Research: Modern Portfolio Theory optimizes conservation practices
Post Your Comments:
Related Image:
Research: Fructose not responsible for increase in non-alcoholic fatty liver disease
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... shareholders, Clean Technology Fund I, LP and Clean Technology ... based venture capital funds which together hold approximately 59% ... diluted, as converted basis), that they have entered into ... holdings in Biorem to TUS Holdings Co. Ltd. ("TUS") ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former ... of the University of North Carolina Kenan-Flagler Business School effective June ... UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes and ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: